Asia Pacific Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class (Immunosuppressant and Immunomodulators), Route of Administration (Injectable and Oral), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce)
Market Introduction
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. It is a potentially debilitating disease, causing disruption in communication and coordination functions of the body.
Get more information on this report :
Market Overview and Dynamics
The Asia Pacific multiple sclerosis therapeutics market is expected to reach US$ 7,130.85 million by 2027 from US$ 4,129.20 million in 2019; it is estimated to grow at a CAGR of 7.2% from 2020 to 2027. The growth of the market is attributed to a few key driving factors such as significant investments in research & development and proactive government support for multiple sclerosis therapeutics. However, the high cost of the multiple sclerosis treatment hinders the market growth. Multiple sclerosis is a widespread disabling neurological condition that is mostly diagnosed in people in the age group of 20–50 years. The market is witnessing significant investments in clinical research and developments. Many pharmaceutical companies are focussing on developing novel therapies for the treatment of MS. Increased research have also paved the way for many research collaborations between pharmaceutical companies and research institutes. Increased research on various novel candidates has resulted in strengthening the pipeline portfolio of leading and small-scale pharmaceutical companies. The expected launch of these pipeline candidates drives the growth of the Asia Pacific multiple sclerosis treatment market. Also, the rising prevalence of the disease has forced governments of many countries to take proactive measures through guidelines and recommendations. Various awareness initiatives are also being launched by government associations to educate patients regarding MS drugs and treatments options available in the market, which boost the market growth.
Asia Pacific countries are witnessing massive challenges due to the increasing number of COVID-19 confirmed cases. The COVID-19 outbreak has severely affected the healthcare industry, considering the economic conditions in the current situation. Precautionary measures have been taken to control the spread of the novel coronavirus. However, in this measure, hospitals, clinics, diagnostic centers, and ambulatory surgery centers (ASCs) are not attending any general patient on priority. Universities across Asia Pacific are closed. Also, access to research labs is restricted, ongoing projects are postponed, fieldwork is interrupted, and travelling is prohibited. All these factors are restraining the growth of the Asia Pacific multiple sclerosis therapeutics market.
Key Market Segments
The Asia Pacific multiple sclerosis therapeutics market, by drug class, is bifurcated into immunosuppressant and immunomodulators. The immunomodulators segment held a larger share of the market in 2019, whereas the immunosuppressants segment is anticipated to register a higher CAGR in the market during the forecast period.
The Asia Pacific multiple sclerosis therapeutics market, by route of administration, is bifurcated into injectable and oral. The injectable segment held a larger share of the market in 2019, and the same segment is anticipated to register a higher CAGR in the market during the forecast period.
Based on distribution channel, the Asia Pacific multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019, whereas the e-commerce segment is estimated to register the highest CAGR in the market during the forecast period.
Major Sources and Companies Listed
Some of the primary and secondary sources associated with this report on the Asia Pacific multiple sclerosis therapeutics market are the National Center for Biotechnology Information (NCBI), National Health Service (NHS) and Multiple Sclerosis Scientific Research Foundation (MSSRF).
Reasons to buy the report
- Determine prospective investment areas based on a detailed trend analysis Asia Pacific multiple sclerosis therapeutics market over the next years.
- Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
- Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
- Identify the major channels driving the Asia Pacific multiple sclerosis therapeutics market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.
- Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Asia Pacific multiple sclerosis therapeutics market.
ASIA PACIFIC MULTIPLE SCLEROSIS THERAPEUTICS MARKET SEGMENTATION
By Drug Class
- Immunosuppressant
- Immunomodulators
By Route of Administration
- Injectable
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
By Country
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Company Profiles
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD
- Biogen
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Multiple Sclerosis Therapeutics Market – By Drug Class
1.3.2 Asia Pacific Multiple Sclerosis Therapeutics Market – By Route of Administration
1.3.3 Asia Pacific Multiple Sclerosis Therapeutics Market – By Distribution Channel
1.3.4 Asia Pacific Multiple Sclerosis Therapeutics Market – By Country
2. Multiple Sclerosis Therapeutics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Multiple Sclerosis Therapeutics– Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific – PEST Analysis
4.3 Expert Opinions
5. Multiple Sclerosis Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Multiple Sclerosis (MS)
5.1.2 Rising Funding for Multiple Sclerosis Research
5.2 Market Restraints
5.2.1 High Cost of Multiple Sclerosis Treatment
5.3 Market Opportunities
5.3.1 Increasing Awareness About Multiple Sclerosis
5.4 Future Trends
5.4.1 Development and Launch of Innovative Products
5.5 Impact analysis
6. Multiple Sclerosis Therapeutics Market – Asia Pacific Analysis
6.1 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue Forecast and Analysis
7. Multiple Sclerosis Therapeutics Market Analysis – By Drug Class
7.1 Overview
7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Immunosuppressant
7.3.1 Overview
7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Immunomodulators
7.4.1 Overview
7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8. Multiple Sclerosis Therapeutics Market Analysis – By Route of Administration
8.1 Overview
8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
8.3 Injectable
8.3.1 Overview
8.3.2 Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Oral
8.4.1 Overview
8.4.2 Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9. Multiple Sclerosis Therapeutics Market Analysis – By Distribution Channel
9.1 Overview
9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.5 E-Commerce
9.5.1 Overview
9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
10. Multiple Sclerosis Therapeutics Market Analysis and Forecast To 2027 – Asia Pacific Analysis
10.1 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027
10.1.1 Overview
10.1.2 Asia Pacific Multiple Sclerosis Therapeutics Market share, By Country (2019 & 2027) (%)
10.1.3 China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.3.1 China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.3.2 China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.3.3 China Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
10.1.3.4 China Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.4 Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.4.1 Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.4.2 Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.4.3 Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
10.1.4.4 Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.5 India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.5.1 India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.5.2 India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.5.3 India Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
10.1.5.4 India Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.6 South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.6.1 South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.6.2 South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.6.3 South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.6.4 South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.7 Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.7.1 Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.7.2 Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.7.3 Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
10.1.7.4 Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.8 Rest of Asia Pacific: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11. Impact of COVID-19 Pandemic on Asia Pacific Multiple Sclerosis Therapeutics Market
11.1 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Novartis AG
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Takeda Pharmaceutical Company Limited
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 F. HOFFMANN-LA ROCHE LTD.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Biogen
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 2. China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
Table 3. China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 4. Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 5. Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
Table 6. Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 7. India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 8. India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
Table 9. India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 10. South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 11. South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 12. South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 13. Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 14. Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
Table 15. Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 19. Organic Developments Done By Companies
Table 20. Inorganic Developments Done By Companies
Table 21. Glossary of Terms, Multiple sclerosis therapeutics Market
LIST OF FIGURES
Figure 1. Multiple Sclerosis Therapeutics Market Segmentation
Figure 2. Multiple Sclerosis Therapeutics Market Segmentation, By Country
Figure 3. Multiple Sclerosis Therapeutics Market Overview
Figure 4. Immunomodulators Segment by Drug Class Held the Larger Share of Asia Pacific Multiple Sclerosis Therapeutics Market
Figure 5. Asia Pacific Multiple Sclerosis Therapeutics Market – Leading Country Markets (US$ Million)
Figure 6. Asia Pacific PEST Analysis
Figure 7. Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Asia Pacific Multiple Sclerosis Therapeutics Market – Revenue Forecast and Analysis – 2019- 2027
Figure 9. Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
Figure 10. Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 11. Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 12. Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
Figure 13. Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 14. Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 15. Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
Figure 16. Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 17. Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 18. E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 19. Asia Pacific Multiple Sclerosis Therapeutics Market Overview, by Country (2019)
Figure 20. Asia Pacific Multiple Sclerosis Therapeutics Market share, By Country (2019 & 2027) (%)
Figure 21. China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. India Multiple Sclerosis Therapeutic Market Revenue And Forecasts to 2027 (US$ Mn)
Figure 24. South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD
- Biogen
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific multiple sclerosis therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific multiple sclerosis therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.